Servier Canada Inc.
VENIXXA™ (micronized purified flavonoid fraction) – PRESS RELEASE

Press release
For immediate release

Servier Canada announces the launch of VENIXXA™, an over-the-counter oral treatment to relieve signs and symptoms of chronic venous disease and hemorrhoids.

Laval, Québec – November 10th, 2017 – Servier Canada announces that VENIXXA™ (micronized purified flavonoid fraction, MPFF), is now available in pharmacies as an over-the-counter oral treatment for patients with mild-to-moderate chronic venous disease or hemorrhoidal disease. VENIXXA™ has been extensively tested in various controlled trials and large registries and is currently available in more than 33 countries around the world.

Chronic venous disease of the legs is characterized by signs and symptoms ranging from a sensation of heavy and/or painful legs, night cramps, spider and varicose veins, edema or ulcers. In the Vein Consult Program—an international, observational survey completed by 6232 general practitioners, it was estimated that approximately 74% of adults suffer from mild-to-moderate chronic venous disease. “As physicians, we have very few options available for these patients apart from mechanical treatments such as compression stockings and endovenous procedures. Although these are very good alternatives, a treatment that addresses the inflammatory process and loss of venous tone related to venous disease is welcome” stated Dr. Douglas Hill, President of the Canadian Society of Phlebology.

Hemorrhoids are a common condition among adults in North America; it is estimated that at least 50% of the population +50 years old has suffered from hemorrhoids at one point in their life. The most common signs and symptoms related to this disease are pain, bleeding and discomfort.

Patients often experience a decline in their quality of life as each of these diseases progresses.

Servier Canada
The over-the-counter drug market is expanding in Canada, and Servier Canada is proud to enter this market. “The launch of VENIXXA™ stems from Servier’s priority to provide effective and innovative treatment options, to Canadian patients. We will leverage our international expertise in vascular disease, to raise awareness of chronic venous disease, hemorrhoidal disease and their consequences, as well as to work with health care providers to ensure that patients are provided with appropriate care.” stated Frederic Fasano, Chief Executive Officer of Servier Canada.

Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of
excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.

Servier Canada was established in 1978 in Laval, Quebec and employs over 300 people across Canada. Servier Canada is currently marketing medicines in Cardiology, Hematology and Diabetes, and will soon market oncology products indicated as treatment options in hematological malignancies. For additional information please visit our website at www.servier.ca.

Media relations:
Nadine DOUCET
Servier Canada
(Office) 450-978-9700, ext. 4225
(Cell) 514-601-4881
nadine.doucet@servier.com
Website: www.servier.ca